Kimberly Parry

Kimberly Parry

Associate

Technology Transactions

Kimberly Parry is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions.

During law school, Kimberly served as the Editor-in-Chief of the Michigan Technology Law Review. Additionally, she served as a student attorney in the International Transactions Clinic and provided research support to University of Michigan’s Innovation Partnerships.

Experience

Kimberly Parry is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions.

Education

J.D., University of Michigan Law School, 2022Editor-in-Chief, Michigan Technology Law Review
B.S., Neurobiology, Physiology, and Behavior, University of California, Davis, 2016

Admissions

State Bar of California

Credentials

Education

J.D., University of Michigan Law School, 2022Editor-in-Chief, Michigan Technology Law Review
B.S., Neurobiology, Physiology, and Behavior, University of California, Davis, 2016

Admissions

State Bar of California

Recent Insights

Client Highlights

On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.

Learn More

Client Highlights

On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.

Learn More